Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18836482 
van Gorp AG, et al. (2009) AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28, 95-106 18836482
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
4-HT increase
LY294002 4-HT inhibit treatment-induced increase
rapamycin 4-HT no effect upon treatment-induced increase
U0126 4-HT no effect upon treatment-induced increase
rapamycin, LY294002 4-HT inhibit treatment-induced increase
U0126, LY294002 4-HT inhibit treatment-induced increase
U0126, rapamycin, LY294002 4-HT inhibit treatment-induced increase
U0126, rapamycin 4-HT no effect upon treatment-induced increase
IL-3 increase
LY294002 IL-3 inhibit treatment-induced increase
Akt-I-1 IL-3 inhibit treatment-induced increase
A-443654 IL-3 no effect upon treatment-induced increase
IL-3 increase
rapamycin IL-3 no effect upon treatment-induced increase
rapamycin no change compared to control
insulin increase
LY294002 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin insulin no effect upon treatment-induced increase
LY294002 no change compared to control
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
insulin increase sight increase
Akt inhibitor VIII no change compared to control
Akt inhibitor VIII insulin inhibit treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
U0126, rapamycin insulin no effect upon treatment-induced increase
LY294002 no change compared to control
rapamycin no change compared to control
U0126 no change compared to control
U0126, rapamycin no change compared to control

S406-p - eIF4B (mouse)
Orthologous residues
eIF4B (human): S406‑p, eIF4B (mouse): S406‑p, eIF4B (rat): S406‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
LY294002 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
insulin increase
Akt inhibitor VIII insulin inhibit treatment-induced increase
Akt inhibitor VIII no change compared to control
Downstream Regulation
 Effect of modification (process):  translation, altered

S422-p - eIF4B (mouse)
Orthologous residues
eIF4B (human): S422‑p, eIF4B (mouse): S422‑p, eIF4B (rat): S422‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
4-HT increase
rapamycin 4-HT no effect upon treatment-induced increase
4-HT increase
LY294002 4-HT inhibit treatment-induced increase
rapamycin 4-HT no effect upon treatment-induced increase
U0126 4-HT no effect upon treatment-induced increase
rapamycin, LY294002 4-HT inhibit treatment-induced increase
U0126, LY294002 4-HT inhibit treatment-induced increase
U0126, rapamycin, LY294002 4-HT inhibit treatment-induced increase
U0126, rapamycin 4-HT no effect upon treatment-induced increase
IL-3 increase
LY294002 IL-3 inhibit treatment-induced increase
Akt-I-1 IL-3 inhibit treatment-induced increase
A-443654 IL-3 no effect upon treatment-induced increase
IL-3 increase
rapamycin IL-3 no effect upon treatment-induced increase
rapamycin no change compared to control
insulin increase
LY294002 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin insulin no effect upon treatment-induced increase
LY294002 no change compared to control
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
insulin increase
amino acid starvation insulin no effect upon treatment-induced increase
amino acid starvation no change compared to control
amino acids increase amino acid re-feeding
LY294002 amino acids inhibit treatment-induced increase
rapamycin amino acids inhibit treatment-induced increase
U0126 amino acids no effect upon treatment-induced increase
insulin increase
Akt inhibitor VIII insulin inhibit treatment-induced increase
Akt inhibitor VIII no change compared to control
Downstream Regulation
 Effect of modification (process):  translation, altered

T203-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
U0126, rapamycin insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
insulin increase
amino acid starvation insulin no effect upon treatment-induced increase
amino acid starvation no change compared to control
amino acids no change compared to control amino acid refeeding
Akt inhibitor VIII no change compared to control
Akt inhibitor VIII insulin no effect upon treatment-induced increase

Y205-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
U0126, rapamycin insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
insulin increase
amino acid starvation insulin no effect upon treatment-induced increase
amino acid starvation no change compared to control
amino acids no change compared to control amino acid refeeding
Akt inhibitor VIII no change compared to control
Akt inhibitor VIII insulin no effect upon treatment-induced increase

T183-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
U0126, rapamycin insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
insulin increase
amino acid starvation insulin no effect upon treatment-induced increase
amino acid starvation no change compared to control
amino acids no change compared to control amino acid refeeding
Akt inhibitor VIII no change compared to control
Akt inhibitor VIII insulin no effect upon treatment-induced increase

Y185-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
U0126, rapamycin insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
insulin increase
amino acid starvation insulin no effect upon treatment-induced increase
amino acid starvation no change compared to control
amino acids no change compared to control amino acid refeeding
Akt inhibitor VIII no change compared to control
Akt inhibitor VIII insulin no effect upon treatment-induced increase

S253-p - FOXO1A (mouse)
Orthologous residues
FOXO1A (human): S256‑p, FOXO1A (mouse): S253‑p, FOXO1A (rat): S250‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
4-HT increase
rapamycin 4-HT no effect upon treatment-induced increase

T32-p - FOXO3A (mouse)
Orthologous residues
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
rapamycin IL-3 no effect upon treatment-induced increase
rapamycin no change compared to control

S21-p - GSK3A (mouse)
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
LY294002 IL-3 inhibit treatment-induced increase
Akt-I-1 IL-3 inhibit treatment-induced increase
A-443654 IL-3 no effect upon treatment-induced increase
insulin increase
Akt inhibitor VIII insulin inhibit treatment-induced increase
Akt inhibitor VIII no change compared to control
insulin increase
LY294002 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
U0126, rapamycin insulin no effect upon treatment-induced increase
LY294002 no change compared to control
rapamycin no change compared to control
U0126 no change compared to control
U0126, rapamycin no change compared to control

S9-p - GSK3B (mouse)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
LY294002 IL-3 inhibit treatment-induced increase
Akt-I-1 IL-3 inhibit treatment-induced increase
A-443654 IL-3 no effect upon treatment-induced increase
insulin increase
Akt inhibitor VIII insulin inhibit treatment-induced increase
Akt inhibitor VIII no change compared to control
insulin increase
LY294002 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
U0126, rapamycin insulin no effect upon treatment-induced increase
LY294002 no change compared to control
rapamycin no change compared to control
U0126 no change compared to control
U0126, rapamycin no change compared to control

T412-p - p70S6K (mouse)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
rapamycin IL-3 inhibit treatment-induced increase
rapamycin no change compared to control
insulin increase
amino acid starvation insulin no effect upon treatment-induced increase
amino acid starvation no change compared to control
amino acids increase amino acid re-feeding
LY294002 amino acids inhibit treatment-induced increase
rapamycin amino acids inhibit treatment-induced increase
U0126 amino acids no effect upon treatment-induced increase

S235-p - S6 (mouse)
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
4-HT increase
rapamycin 4-HT inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase
U0126 insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
IL-3 increase
LY294002 IL-3 inhibit treatment-induced increase
Akt-I-1 IL-3 inhibit treatment-induced increase
A-443654 IL-3 no effect upon treatment-induced increase
insulin increase sight increase
Akt inhibitor VIII no change compared to control
Akt inhibitor VIII insulin inhibit treatment-induced increase

S236-p - S6 (mouse)
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), 3T3 (fibroblast) [InsR (mouse), transfection], BaF3 ('B lymphocyte, precursor'), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  3T3-derived cells overexpressing InsR (A14 cells)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
4-HT increase
rapamycin 4-HT inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase
U0126 insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin insulin inhibit treatment-induced increase
U0126, rapamycin, LY294002 insulin inhibit treatment-induced increase
U0126, rapamycin no change compared to control
U0126, rapamycin, LY294002 no change compared to control
IL-3 increase
LY294002 IL-3 inhibit treatment-induced increase
Akt-I-1 IL-3 inhibit treatment-induced increase
A-443654 IL-3 no effect upon treatment-induced increase
insulin increase sight increase
Akt inhibitor VIII no change compared to control
Akt inhibitor VIII insulin inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.